X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA STERLING BIOTECH NATCO PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 24.1 -1.8 - View Chart
P/BV x 18.3 0.1 26,665.6% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
STERLING BIOTECH
Dec-13
NATCO PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs87711 8,352.4%   
Low Rs4243 12,455.9%   
Sales per share (Unadj.) Rs223.426.8 833.5%  
Earnings per share (Unadj.) Rs31.1-15.0 -207.7%  
Cash flow per share (Unadj.) Rs40.3-5.5 -737.2%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.554.9 399.9%  
Shares outstanding (eoy) m33.07267.87 12.3%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.90.3 1,122.5%   
Avg P/E ratio x20.9-0.5 -4,504.3%  
P/CF ratio (eoy) x16.1-1.3 -1,269.1%  
Price / Book Value ratio x3.00.1 2,339.3%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5041,862 1,155.1%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m1,128547 206.2%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m7,3897,181 102.9%  
Other income Rs m16743 392.3%   
Total revenues Rs m7,5567,223 104.6%   
Gross profit Rs m1,793947 189.4%  
Depreciation Rs m3042,543 12.0%   
Interest Rs m3664,377 8.4%   
Profit before tax Rs m1,290-5,931 -21.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309-1,924 -16.0%   
Profit after tax Rs m1,027-4,007 -25.6%  
Gross profit margin %24.313.2 184.1%  
Effective tax rate %23.932.4 73.8%   
Net profit margin %13.9-55.8 -24.9%  
BALANCE SHEET DATA
Current assets Rs m3,68114,335 25.7%   
Current liabilities Rs m3,12349,809 6.3%   
Net working cap to sales %7.6-494.0 -1.5%  
Current ratio x1.20.3 409.6%  
Inventory Days Days89403 22.2%  
Debtors Days Days59171 34.4%  
Net fixed assets Rs m7,68555,432 13.9%   
Share capital Rs m331268 123.4%   
"Free" reserves Rs m6,67013,935 47.9%   
Net worth Rs m7,25914,701 49.4%   
Long term debt Rs m9559,478 10.1%   
Total assets Rs m11,95773,988 16.2%  
Interest coverage x4.5-0.4 -1,274.0%   
Debt to equity ratio x0.10.6 20.4%  
Sales to assets ratio x0.60.1 636.7%   
Return on assets %11.70.5 2,326.9%  
Return on equity %14.2-27.3 -51.9%  
Return on capital %20.7-6.4 -322.5%  
Exports to sales %39.425.9 151.9%   
Imports to sales %5.70.2 3,355.2%   
Exports (fob) Rs m2,9081,860 156.4%   
Imports (cif) Rs m42112 3,452.5%   
Fx inflow Rs m3,4451,860 185.3%   
Fx outflow Rs m70325 2,823.6%   
Net fx Rs m2,7431,835 149.5%   
CASH FLOW
From Operations Rs m1,4401,719 83.8%  
From Investments Rs m-1,089-3,148 34.6%  
From Financial Activity Rs m-3531,426 -24.7%  
Net Cashflow Rs m-1-3 43.8%  

Share Holding

Indian Promoters % 52.0 33.9 153.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.0 -  
FIIs % 16.6 9.9 168.0%  
ADR/GDR % 0.0 16.9 -  
Free float % 26.0 39.3 66.2%  
Shareholders   25,395 21,482 118.2%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS